Article
Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study.
European journal of cancer (Oxford, England : 1990) - 1 Nov 2024
Zhou Qing, Yang Nong, Zhao Mingfang, Huang Dingzhi, Zhao Jun, Yu Yan, Yuan Ying, Sun Longhua, Dong Xiaorong, Zhang Tongmei, Chu Qian, Li Xingya, Meng Xiangjiao, Wang Huijuan, Wang Xiang, Wu Dongde, Hu Sheng, Shan Jinlu, Liu Lian, Sun Meili, Zhang Zhiye, Zhu Haibo, Huang Jingjing, Huang Mengna, Cheng Lingge, Zhang Sujie, Zhou Hui, Wu Yi-Long
Abstract excerpt
BACKGROUND: IBI351 is an irreversible and covalent inhibitor of KRAS G12C. Despite FDA approval of two KRAS G12C inhibitors, there are still significant unmet clinical needs in Chinese patients and ongoing concerns about the optimal dosage. Herein, we presented the phase Ia/Ib study of IBI351 monotherapy in Chinese patients with advanced solid tumors harboring KRAS G12C mutation. METHODS: In phase Ia dose...
Topics
Join the communities discussing this publication.